Still, the main factor defining their anti-PCa effects, relative to TMPRSS2-ERG-fusion positivity, appears to be the ability of the NSAIDs to significantly affect the proliferative growth phase of the fusion-positive tumors. Here, TMPRSS2 is linked to posterior cortical atrophy.